Evaluation of the Effects of Aquatic Therapy on Activities of Daily Living, Walking, Balance, Posture, Pain, and Depression in Parkinson's Patients
1 other identifier
interventional
42
1 country
2
Brief Summary
Parkinson's Disease (PD) is a progressive neurodegenerative disorder characterized by motor symptoms such as bradykinesia, tremors, and postural instability, as well as various non-motor symptoms. Conventional land-based rehabilitation is standard; however, aquatherapy-utilizing water's buoyancy, hydrostatic pressure, and viscosity-offers a promising alternative to improve balance and mobility while reducing fall risks. This study aims to evaluate the effects of aquatherapy on gait, balance, posture, freezing of gait, activities of daily living (ADL), pain, and depression in Turkish PD patients. This is a prospective, single-blind, randomized controlled trial involving 42 patients at Ankara City Hospital. Participants will be divided into two groups:
- Group 1 (Control): Home-based exercise program (5 days/week for 6 weeks).
- Group 2 (Intervention): Home-based exercises plus supervised aquatherapy (3 sessions/week, 45 minutes each, in a 30-32°C pool). The study utilizes high-tech objective measurements and validated scales:
- Gait \& Posture: Zebris Gait Analysis (spatiotemporal parameters) and Diers Formetric 4D (topographical posture analysis).
- Balance: HUR-Smart Balance device and the Berg Balance Scale.
- Clinical Scales: PDQ-39 (quality of life), Freezing of Gait Questionnaire, Falls Efficacy Scale, MMSE (cognitive), Beck Depression Inventory, and VAS (pain). This research is noteworthy as the first aquatherapy study among Turkish PD patients to utilize a large sample size and standardized aquatic exercise protocols. It seeks to provide a comprehensive analysis of both motor and non-motor improvements, potentially establishing aquatherapy as a superior adjunctive treatment for enhancing functional independence in Parkinson's patients. Primary hypothesis or outcome measure : Parkinson's Disease Questionnaire-39 . PDQ-39 is a patient-reported outcome measure designed to evaluate the health-related quality of life in Parkinson's patients across eight specific domains, including mobility, activities of daily living, and emotional well-being.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable parkinson-disease
Started Jan 2025
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2025
CompletedFirst Submitted
Initial submission to the registry
January 23, 2026
CompletedFirst Posted
Study publicly available on registry
February 5, 2026
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 1, 2026
ExpectedStudy Completion
Last participant's last visit for all outcomes
August 1, 2026
February 5, 2026
February 1, 2026
1.6 years
January 23, 2026
February 1, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Parkinson's Disease Questionnaire-39
Patients' quality of life will be evaluated using the Parkinson's Disease Questionnaire-39 (PDQ-39).The PDQ-39 is a 39-item questionnaire that covers eight distinct dimensions of functioning and well-being. The domains include: Mobility , Activities of Daily Living, Emotional Well-being , Stigma, Social Support, Cognition, Communicatio, Bodily Discomfort.The questionnaire uses a 5-point Likert response format where patients rate their experiences from "never" (0) to "always" (4). For each of the eight dimensions, a score is calculated and normalized to a 0-100 scale using the formula:Dimension Score = (Sum of Item Scores / Maximum Possible Score for Dimension) × 100 each dimension the minimum possible score is 0 and the maximum possible score is 100 after normalization. Considering the entire PDQ-39, the raw total score ranges from 0 to 156, where 0 represents the best possible quality of life and 156 the worst possible quality of life.
From enrollment to the end of treatment at 6 weeks
Secondary Outcomes (1)
Berg Balance Scale
From enrollment to the end of treatment at 6 weeks.
Study Arms (2)
Arm 1: Control Group (Home-based Exercise)
EXPERIMENTALControl Group (Home-based Exercise)
Arm2: Experimental Group
EXPERIMENTALExperimental Group (Aquatherapy + Home-based Exercise)
Interventions
The specific aquatic exercise protocol for Group 2, conducted in a 120 cm deep therapy pool at 30-32°C, includes the following exercises: Gait and Mobility: Water walking (forward and backward) and side-stepping. Dynamic Balance: Forward and lateral lunges, and single-leg stance/balance drills. Lower Extremity Strengthening: Hip kicks performed at the pool wall (flexion, extension, and abduction) and standing knee raises. Upper Body and Coordination: Arm raises (multi-directional) and deep-water cycling movements. Home Exercise Component: In addition to aquatic sessions, patients will continue land-based exercises including posture correction, flexibility/stretching, balance-coordination training, and strengthening.
Group 1 patients will be prescribed a home exercise program at least 5 days per week for a duration of 6 weeks
Eligibility Criteria
You may qualify if:
- Having a diagnosis of Idiopathic Parkinson's Disease between the ages of 40-80 and consenting to the treatment.
- Being regularly followed by a neurologist and having a stable medical treatment regimen for at least 3 months.
- Having a disease stage between 1-3 according to the Modified Hoehn-Yahr Staging Scale (MHY).
- A score of 24 or higher on the Mini-Mental State Examination (MMSE).
- Being able to verticalize independently and ambulate with or without assistance.
You may not qualify if:
- Having orthopedic, rheumatological, or non-Parkinson's neurological disorders that affect functional status.
- Having a medical treatment regimen that has been modified within the last 3 months.
- Presence of Atypical Parkinson's Disease.
- Visual impairment.
- Presence of dementia.
- Decompensated cardiac or respiratory failure.
- Diabetes insipidus.
- Presence of systemic infection.
- Impaired skin integrity or the presence of skin infections.
- Increased sensitivity to inhaled steam or water chemicals.
- History of epilepsy or asthma.
- Urinary or fecal incontinence.
- Refusal to participate in or consent to the treatment.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (2)
Bilkent City Hospital
Çankaya, Ankara, 06800, Turkey (Türkiye)
Bilkent City Hospital
Ankara, ÇANKAYA, 06800, Turkey (Türkiye)
Related Publications (1)
Pinto C., et al. (2019). "The Effects of Hydrotherapy on Balance, Functional Mobility, Motor Status, and Quality of Life in Patients with Parkinson Disease: A Systematic Review and Meta-analysis", PM R, 11(3), 278-291. https://doi.org/10.1016/j.pmrj.2018.09.031
BACKGROUND
Related Links
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Halil Uçan, Prof. Doctor
Bilkent City Hospital
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- PARTICIPANT
- Masking Details
- The study was designed as a single-blind trial, where participants were kept unaware of their group assignments.
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Assistant Doctor
Study Record Dates
First Submitted
January 23, 2026
First Posted
February 5, 2026
Study Start
January 1, 2025
Primary Completion (Estimated)
August 1, 2026
Study Completion (Estimated)
August 1, 2026
Last Updated
February 5, 2026
Record last verified: 2026-02
Data Sharing
- IPD Sharing
- Will not share
Individual participant data will not be shared publicly to protect patient confidentiality and ensure strict adherence to personal data protection laws. The raw data contains sensitive health information that could potentially lead to the de-identification of participants, which would violate the ethical terms outlined in the informed consent forms